Kuros Biosciences and Medtronic Enter Strategic Agreement

Kuros Biosciences USA, Inc. has entered into an exclusive five-year strategic sales agreement with Medtronic's spinal division. Medtronic will act as the sole sales agent for Kuros' MagnetOs bone grafting technology in designated U.S. spine surgery markets. This agreement enhances a prior trial partnership, expanding access to MagnetOs, supported by extensive clinical data.

Kuros maintains responsibility for contracts and revenue in uncontracted areas and markets outside spine surgeries. The collaboration aims to increase Kuros' U.S. market presence, promoting greater adoption of its innovative bone healing technology.

Chris Fair, CEO of Kuros, described the agreement as a pivotal milestone that will aid in optimizing operations and sustaining rapid revenue growth through both Medtronic channels and direct sales.